← Back

LeMaitre Vascular Inc

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants for vascular surgery across the Americas, Europe, the Middle East, Africa, and Asia Pacific. Its offerings include allografts, embolectomy and thrombectomy catheters, occlusion and perfusion catheters, and cryopreservation services. The company also provides biologic products such as Artegraft, XenoSure, VascuCel, and CardioCel patches, carotid shunts, biosynthetic vascular grafts, a phlebectomy system, LifeSpan vascular grafts, and vascular grafts. Additional products include radiopaque tape, valvulotomes, and closure systems. It sells through a direct sales force and distributors. Formerly Vascutech, Inc., it changed its name to LeMaitre Vascular, Inc. in April 2001, was incorporated in 1983, and is headquartered in Burlington, Massachusetts.

Country
Price · split & dividend adjusted
News & notes moving LMAT
United States
LMAT▲2

LeMaitre Vascular reports higher Q2 sales and net income, issues new guidance

LeMaitre Vascular reported second quarter 2026 sales of US$70.38 million, up from US$64.23 million a year earlier, with net income rising to US$17.05 million from US$13.78 million. Diluted earnings per share from continuing operations were US$0.74 compared with US$0.60 in the prior year period. For the first six months of 2026, sales reached US$136.93 million versus US$124.10 million, and net income was US$32.73 million against US$24.79 million. The company also issued new earnings guidance and affirmed its quarterly dividend. The results come amid a 20% share price decline over the past 30 days, with analysts estimating a fair value of US$118.75 per share, suggesting the stock is 31.4% undervalued relative to the latest close of US$81.45.
LMAT ▲
LMAT · Capital · Positive Higher Q2 sales and net income, new guidance, and affirmed dividend are positive financial results.
Read original ↗
Simply Wall St·57dRead more →
United States
LMAT▼

LeMaitre Vascular Shares Decline Despite Strong Earnings as Investors Take Profits

LeMaitre Vascular, Inc. reported strong first-quarter results with 10% organic revenue growth, gross margins of 72.1%, and adjusted earnings per share of $0.68, exceeding the consensus estimate of $0.66. Despite these solid fundamentals, the stock fell after the earnings release as investors took profits in one of the medical device sector's strongest performers. Prior to reporting first-quarter results on May 5, 2026, LMAT shares had appreciated approximately 38% year-to-date. Conestoga Capital Advisors, which highlighted the company in its second-quarter 2026 investor letter, continues to believe LeMaitre Vascular is well positioned for attractive revenue and earnings growth, supported by its differentiated vascular product portfolio and consistent execution.
LMAT ▼
LMAT · Capital · Negative Stock fell despite strong earnings as investors took profits after a 38% YTD run.
Read original ↗
Insider Monkey·59dRead more →
LMAT

LeMaitre Vascular to Report Earnings Tuesday After Market Close

Medical device company LeMaitre Vascular will announce its earnings results this Tuesday after market close. The market expects revenue to grow 11.5% year on year, a slowdown from the 15% increase recorded in the same quarter last year. Analysts have generally reconfirmed their estimates over the last 30 days, though the company has missed Wall Street revenue estimates multiple times over the past two years. LeMaitre shares are down 2.5% over the last month, heading into earnings with an average analyst price target of $118.75 compared to the current share price of $101.32.
LMAT
LMAT · Capital · Neutral Earnings report upcoming; expectations and past misses create uncertainty.
Read original ↗
Yahoo Finance·62dRead more →
LMAT2

Surgical Equipment Stocks Post Strong Q1, Integra LifeSciences Shares Surge 64.9%

Surgical equipment and consumables specialty stocks reported a strong first quarter, with the four companies tracked by StockStory beating revenue consensus by 2.7% on average. Integra LifeSciences posted revenue of $391.9 million, up 2.4% year-on-year and 2.6% above estimates, while raising its full-year EPS guidance; its shares have surged 64.9% since the report. Intuitive Surgical delivered the biggest beat, with revenue of $2.77 billion exceeding expectations by 5.8%, though its stock fell 10.6%. Teleflex grew revenue 32.3% to $548.3 million but missed full-year EPS guidance, and LeMaitre Vascular reported $66.55 million in revenue, in line with estimates, while beating next-quarter EPS guidance.
IART ▲ISRG ▼TFX ▼LMAT
IART · Capital · Positive Beat revenue estimates and raised full-year EPS guidance, driving shares up 64.9%.
ISRG · Capital · Negative Despite biggest revenue beat, stock fell 10.6% (likely due to market expectations or other factors).
TFX · Capital · Negative Revenue grew 32.3% but missed full-year EPS guidance.
LMAT · Capital · Neutral Revenue in line with estimates but beat next-quarter EPS guidance; mixed signals.
Read original ↗
StockStory·103dRead more →
© 2026 MarketDXAsset